MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'edwards lifesciences'. Sat, 03 Sep 2011 03:01:52 +0100 http://www.medworm.com/index.php?rid=3733080&cid=t_197854_87_f&fid=38368&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FDisruptiveWomenInHealthCare%2F%7E3%2FiLuybO-gO8g%2F The Society for Women’s Health Research cordially invites you to attend: WHAT A DIFFERENCE AN X MAKES: THE STATE OF WOMEN’S HEALTH RESEARCH Friday, July 16, 2010 9:00 am – 4:00 pm Barbara Jordan Conference Center Kaiser Family Foundation 1330 G Street, NW, Washington, DC 20005 This scientific conference will highlight advances in sex differences research and its implications on health and disease. Registration fee for the conference is $35 per person, $20 for students. RSVP NOW! Topics and speakers include: Pain and the Musculoskeletal System – Carmen R. Green, MD and Mary O’Connor, MD The Brain - Kathryn M. Magruder, MPH, PhD and Cerise Elliott, PhD The Immune System – Sabra Klein, PhD and Rhonda Voskuhl, MD Cardio/Cerebrovascular Disease and Therape... Disruptive Women in Health Care blogs http://www.medworm.com/rss/comments.php?id=3733080 Wed, 07 Jul 2010 13:48:01 +0100 3733080 http://www.medworm.com/index.php?rid=2065541&cid=t_197854_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F493460251%2F The maker of replacement heart valves plans in the second half of 2009 to post on its web site ties with docs who are paid more than $5,000 a year in consulting fees, royalties and honoraria, but will begin targeted tracking of the data on January 1. The move comes with pending legislation that would require drug and device makers to disclose how much money they give docs, although some drugmakers, such as Merck and Lilly, have already taken steps to do so. Also, several device makers disclosed payments as part of a deal with federal prosecutors last year that resolved allegations of payoffs for consulting deals (take a look). “Medical innovation is dependent on these physician partnerships, and we believe that bringing transparency to these relationships will help the public better... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2065541 Tue, 23 Dec 2008 20:43:52 +0100 2065541 http://www.medworm.com/index.php?rid=2013831&cid=t_197854_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F474684337%2F The US Senate Finance Committee is investigating a heart valve made by Edwards Lifesciences and whether the device was implanted in patients by a Northwestern Memorial Hospital surgeon, who invented the device and receives royalties from Edwards, even though FDA approval was lacking. Apparently, Patrick McCarthy, a cardiothoracic surgeon, allegedly used the Myxo ETlogix 5100 Ring without an Investigational Device Exemption (IDE), which would allow the device to be used in a clinical study to collect data in support of an application to the FDA for approval, according to Chuck Grassley, who is the ranking Republican on the committee. The allegations were made by Nalini Rajamannan, an associate professor and valve director of the Bluhm Cardiovascular Institute at Northwestern University’s ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2013831 Thu, 04 Dec 2008 14:01:38 +0100 2013831 http://www.medworm.com/index.php?rid=1708996&cid=t_197854_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2008%2F08%2Fmore-questions-about-conflicts-of.html Two years ago, we posted about questions whether the "Surviving Sepsis" campaign was driven by marketing as well as science. Then, we discussed a commentary in the New England Journal of Medicine which asserted that the campaign was part of an effort by Eli Lilly & Co to market Xigris (recombinant human activated protein C, or rhAPC, also known as drotrecogin alfa [activated]) for the treatment of sepsis.(1)The Wall Street Journal just published an article questioning another aspect of that campaign. In 2001 a clinical trial in the New England Journal of Medicine by Rivers et al reported favorable results for early goal-directed therapy in the treatment of sepsis.(2) This therapy incorporated continuous monitoring of oxygen in the blood using a special central venous catheter capable ... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=1708996 Sat, 16 Aug 2008 21:04:00 +0100 1708996